Contact this trialFirst, we need to learn more about you.
Hypomethylation Agent
Pembrolizumab + Decitabine with or without Venetoclax for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Recruiting3 awardsPhase 1
Duarte, California
This trial is testing the combination of the immunotherapy drug pembrolizumab with the drugs decitabine and venetoclax, to see if it is safe and effective in treating patients with newly-diagnosed, recurrent, or refractory acute myeloid leukemia or myelodysplastic syndrome.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service